JP2014515758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515758A5 JP2014515758A5 JP2014508507A JP2014508507A JP2014515758A5 JP 2014515758 A5 JP2014515758 A5 JP 2014515758A5 JP 2014508507 A JP2014508507 A JP 2014508507A JP 2014508507 A JP2014508507 A JP 2014508507A JP 2014515758 A5 JP2014515758 A5 JP 2014515758A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- alkylene
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims 27
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 9
- 206010011878 Deafness Diseases 0.000 claims 6
- 208000014769 Usher Syndromes Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000010370 hearing loss Effects 0.000 claims 6
- 231100000888 hearing loss Toxicity 0.000 claims 6
- 208000016354 hearing loss disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000002207 retinal effect Effects 0.000 claims 6
- 238000010276 construction Methods 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 239000011324 bead Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 0 *c1c(c(-c2c(*)c(*)c(*)c(*)c2*)n[n]2*)c2nnc1-c1ccccc1 Chemical compound *c1c(c(-c2c(*)c(*)c(*)c(*)c2*)n[n]2*)c2nnc1-c1ccccc1 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478642P | 2011-04-25 | 2011-04-25 | |
| US61/478,642 | 2011-04-25 | ||
| US201161537908P | 2011-09-22 | 2011-09-22 | |
| US61/537,908 | 2011-09-22 | ||
| US201161576471P | 2011-12-16 | 2011-12-16 | |
| US61/576,471 | 2011-12-16 | ||
| PCT/US2012/034959 WO2012148994A1 (en) | 2011-04-25 | 2012-04-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016044089A Division JP2016193884A (ja) | 2011-04-25 | 2016-03-08 | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515758A JP2014515758A (ja) | 2014-07-03 |
| JP2014515758A5 true JP2014515758A5 (enExample) | 2015-06-18 |
| JP5902293B2 JP5902293B2 (ja) | 2016-04-13 |
Family
ID=47072720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508507A Active JP5902293B2 (ja) | 2011-04-25 | 2012-04-25 | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| JP2016044089A Pending JP2016193884A (ja) | 2011-04-25 | 2016-03-08 | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016044089A Pending JP2016193884A (ja) | 2011-04-25 | 2016-03-08 | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9079909B2 (enExample) |
| EP (1) | EP2701510B1 (enExample) |
| JP (2) | JP5902293B2 (enExample) |
| AU (1) | AU2012249801B2 (enExample) |
| CA (1) | CA2834049C (enExample) |
| ES (1) | ES2625534T3 (enExample) |
| HU (1) | HUE032820T2 (enExample) |
| IL (1) | IL229023A (enExample) |
| PL (1) | PL2701510T3 (enExample) |
| WO (1) | WO2012148994A1 (enExample) |
| ZA (1) | ZA201307961B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6290910B2 (ja) * | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
| US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
| CA2889494C (en) * | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| AU2016274956A1 (en) * | 2015-06-11 | 2017-12-14 | Usher Iii Initiative, Inc. | Methods of treating or preventing a proteopathy |
| CN114585434A (zh) * | 2019-10-23 | 2022-06-03 | 新加坡国立大学 | 用于合成化合物的方法和系统 |
| EP4178580B1 (en) | 2020-07-09 | 2025-11-05 | Usher III Initiative, Inc. | Bf 844 for use in the treatment of cancer |
| WO2023101421A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295550A3 (en) | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| GB0206723D0 (en) * | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel compounds |
| ATE554087T1 (de) * | 2004-10-29 | 2012-05-15 | Abbott Lab | Neue kinaseinhibitoren |
| JP2008518964A (ja) * | 2004-11-01 | 2008-06-05 | ユニバーシティ オブ サザン カリフォルニア | 癌と、血管新生機能に関連する疾患との治療用新規化合物 |
| US20090048285A1 (en) | 2005-01-19 | 2009-02-19 | Benjamin Pelcman | Pyrrolopyridines Useful in the Treatment of Inflammation |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| US20070123508A1 (en) * | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
| US20090306045A1 (en) * | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| BRPI0710723A2 (pt) | 2006-04-14 | 2012-01-31 | Novartis Ag | uso de biarilcarboxamidas no tratamento de distúrbio relacionados à série de reação hedgehog |
| EP2076513A1 (en) | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
| WO2009039420A1 (en) * | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
| WO2009062118A2 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| AU2010356144B2 (en) | 2010-06-24 | 2015-06-04 | Alphabeta Ab | Compound and method for treatment of Alzheimer's disease and familial dementia |
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
| JP6290910B2 (ja) | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2889494C (en) | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| AU2016274956A1 (en) | 2015-06-11 | 2017-12-14 | Usher Iii Initiative, Inc. | Methods of treating or preventing a proteopathy |
-
2012
- 2012-04-25 JP JP2014508507A patent/JP5902293B2/ja active Active
- 2012-04-25 PL PL12777328T patent/PL2701510T3/pl unknown
- 2012-04-25 CA CA2834049A patent/CA2834049C/en active Active
- 2012-04-25 WO PCT/US2012/034959 patent/WO2012148994A1/en not_active Ceased
- 2012-04-25 ES ES12777328.1T patent/ES2625534T3/es active Active
- 2012-04-25 AU AU2012249801A patent/AU2012249801B2/en active Active
- 2012-04-25 EP EP12777328.1A patent/EP2701510B1/en active Active
- 2012-04-25 HU HUE12777328A patent/HUE032820T2/en unknown
-
2013
- 2013-03-08 US US13/791,205 patent/US9079909B2/en active Active
- 2013-10-22 IL IL229023A patent/IL229023A/en active IP Right Grant
- 2013-10-24 ZA ZA2013/07961A patent/ZA201307961B/en unknown
-
2015
- 2015-06-04 US US14/730,994 patent/US9260381B2/en active Active
- 2015-12-28 US US14/980,347 patent/US9549910B2/en active Active
-
2016
- 2016-03-08 JP JP2016044089A patent/JP2016193884A/ja active Pending
- 2016-12-12 US US15/375,959 patent/US9925187B2/en active Active
-
2018
- 2018-03-19 US US15/924,831 patent/US10307422B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509429A5 (enExample) | ||
| JP2011511933A5 (enExample) | ||
| JP2012531433A5 (enExample) | ||
| JP2011207901A5 (enExample) | ||
| JP2013537423A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2013520502A5 (enExample) | ||
| JP2009535462A5 (enExample) | ||
| JP2014509612A5 (enExample) | ||
| JP2012514009A5 (enExample) | ||
| JP2009535358A5 (enExample) | ||
| EP4512481A3 (en) | Binding molecules for bcma and cd3 | |
| JP2015512943A5 (enExample) | ||
| JP2014511682A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2012509265A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| EA200870389A1 (ru) | Стирилпиридиновые производные и их применение для связывания и визуализации амилоидных бляшек | |
| JP2016135784A5 (enExample) | ||
| JP2011057686A5 (enExample) | ||
| JP2013532132A5 (enExample) | ||
| JP2014097964A5 (enExample) | ||
| JP2012519182A5 (enExample) |